Putnam Investments’s TG Therapeutics TGTX Stock Holding History

Putnam Investments’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	$707K	Buy	41,401 +7,390	+22%	+$85.9K	﹤0.01%	884
2023 Q3	$284K	Buy	+34,011	New	+$474K	﹤0.01%	1077
2021 Q3	–	Sell	-231,293	Closed	-$8.97M	–	831
2021 Q2	$8.97M	Buy	231,293 +107,400	+87%	+$4.22M	0.01%	398
2021 Q1	$5.97M	Hold	123,893	–	–	0.01%	465
2020 Q4	$6.45M	Buy	123,893 +29,647	+31%	+$1M	0.01%	455
2020 Q3	$2.52M	Buy	+94,246	New	+$2.17M	0.01%	601
2018 Q3	–	Sell	-41,444	Closed	-$545K	–	1143
2018 Q2	$545K	Sell	41,444 -51,099	-55%	-$703K	﹤0.01%	933
2018 Q1	$1.31M	Buy	+92,543	New	+$1.18M	﹤0.01%	809

Other funds holding TGTX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DGM

Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Putnam Investments's TGTX Position: Q4 2023 in Review

Putnam Investments increased its TG Therapeutics (TGTX) stake by 22% in Q4 2023, buying an estimated $85.9K and bringing the position to 41,401 shares worth $707K. The position accounts for ﹤0.01% of the portfolio, ranked #884.

Putnam Investments first reported a position in TGTX in Q1 2018 and has held it in 8 quarters since. The position peaked at $8.97M in Q2 2021. 235 funds tracked by Wall St. Rank hold TGTX as of Q4 2023.

Putnam Investments held 41,401 shares of TG Therapeutics worth $707K as of Q4 2023.
Putnam Investments bought 7,390 TG Therapeutics shares in Q4 2023, an estimated $85.9K.
TG Therapeutics made up ﹤0.01% of Putnam Investments's portfolio in Q4 2023, its #884 holding.
Putnam Investments first reported a position in TG Therapeutics in Q1 2018 and has held it in 8 quarters since.
Putnam Investments's TG Therapeutics position peaked at $8.97M in Q2 2021.
235 funds tracked by Wall St. Rank held TG Therapeutics as of Q4 2023.

Based on Putnam Investments's 13F filing for Q4 2023, filed 14 Feb 2024.